Emergent Biosolutions (EBS) Competitors

$7.64 -0.05 (-0.65%)

As of 11:25 AM Eastern

EBS vs. JNJ, INVA, NVAX, MNKD, and OPK

Should you buy Emergent Biosolutions stock or one of its competitors? MarketBeat compares Emergent Biosolutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Emergent Biosolutions include Johnson & Johnson (JNJ), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "medical" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Johnson & Johnson has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

In the previous week, Johnson & Johnson had 150 more articles in the media than Emergent Biosolutions. MarketBeat recorded 150 mentions for Johnson & Johnson and 0 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.98 beat Emergent Biosolutions' score of 0.00 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Overall Sentiment
Johnson & Johnson	Positive
Emergent Biosolutions	Neutral

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Johnson & Johnson has a net margin of 21.48% compared to Emergent Biosolutions' net margin of -1.27%. Johnson & Johnson's return on equity of 32.86% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.86%	13.41%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Johnson & Johnson currently has a consensus price target of $265.30, indicating a potential upside of 5.63%. Emergent Biosolutions has a consensus price target of $12.00, indicating a potential upside of 57.07%. Given Emergent Biosolutions' higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.42	$26.80B	$8.63	29.10
Emergent Biosolutions	$742.90M	0.53	$52.60M	-$0.28	N/A

Summary

Johnson & Johnson beats Emergent Biosolutions on 13 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Innoviva?

Innoviva (NASDAQ:INVA) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Innoviva has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Emergent Biosolutions' net margin of -1.27%. Innoviva's return on equity of 33.33% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Emergent Biosolutions	-1.27%	10.76%	4.22%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Innoviva has higher earnings, but lower revenue than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.86	$271.17M	$6.01	3.58
Emergent Biosolutions	$742.90M	0.53	$52.60M	-$0.28	N/A

Innoviva currently has a consensus target price of $36.20, indicating a potential upside of 68.29%. Emergent Biosolutions has a consensus target price of $12.00, indicating a potential upside of 57.07%. Given Innoviva's stronger consensus rating and higher probable upside, research analysts clearly believe Innoviva is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Innoviva's average media sentiment score of 0.00 equaled Emergent Biosolutions'average media sentiment score.

Company	Overall Sentiment
Innoviva	Neutral
Emergent Biosolutions	Neutral

Summary

Innoviva beats Emergent Biosolutions on 11 of the 14 factors compared between the two stocks.

How does Emergent Biosolutions compare to Novavax?

Emergent Biosolutions (NYSE:EBS) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Emergent Biosolutions currently has a consensus target price of $12.00, suggesting a potential upside of 57.07%. Novavax has a consensus target price of $13.00, suggesting a potential upside of 61.59%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Novavax had 5 more articles in the media than Emergent Biosolutions. MarketBeat recorded 5 mentions for Novavax and 0 mentions for Emergent Biosolutions. Novavax's average media sentiment score of 0.41 beat Emergent Biosolutions' score of 0.00 indicating that Novavax is being referred to more favorably in the news media.

Company	Overall Sentiment
Emergent Biosolutions	Neutral
Novavax	Neutral

Emergent Biosolutions has a net margin of -1.27% compared to Novavax's net margin of -14.73%. Emergent Biosolutions' return on equity of 10.76% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Novavax	-14.73%	-14.82%	1.23%

Emergent Biosolutions has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market.

Novavax has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.53	$52.60M	-$0.28	N/A
Novavax	$1.12B	1.18	$440.30M	-$0.58	N/A

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novavax beats Emergent Biosolutions on 10 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to MannKind?

MannKind (NASDAQ:MNKD) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Emergent Biosolutions has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.55	$5.86M	-$0.07	N/A
Emergent Biosolutions	$742.90M	0.53	$52.60M	-$0.28	N/A

In the previous week, MannKind had 7 more articles in the media than Emergent Biosolutions. MarketBeat recorded 7 mentions for MannKind and 0 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.67 beat Emergent Biosolutions' score of 0.00 indicating that MannKind is being referred to more favorably in the media.

Company	Overall Sentiment
MannKind	Positive
Emergent Biosolutions	Neutral

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

Emergent Biosolutions has a net margin of -1.27% compared to MannKind's net margin of -6.63%. Emergent Biosolutions' return on equity of 10.76% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Emergent Biosolutions	-1.27%	10.76%	4.22%

49.6% of MannKind shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MannKind currently has a consensus price target of $8.97, suggesting a potential upside of 123.38%. Emergent Biosolutions has a consensus price target of $12.00, suggesting a potential upside of 57.07%. Given MannKind's stronger consensus rating and higher possible upside, equities analysts plainly believe MannKind is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Emergent Biosolutions beats MannKind on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Emergent Biosolutions has higher revenue and earnings than OPKO Health. Emergent Biosolutions is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A
Emergent Biosolutions	$742.90M	0.53	$52.60M	-$0.28	N/A

In the previous week, OPKO Health had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 1 mentions for OPKO Health and 0 mentions for Emergent Biosolutions. OPKO Health's average media sentiment score of 0.44 beat Emergent Biosolutions' score of 0.00 indicating that OPKO Health is being referred to more favorably in the media.

Company	Overall Sentiment
OPKO Health	Neutral
Emergent Biosolutions	Neutral

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OPKO Health has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 27.57%. Emergent Biosolutions has a consensus target price of $12.00, indicating a potential upside of 57.07%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Emergent Biosolutions has a net margin of -1.27% compared to OPKO Health's net margin of -36.63%. Emergent Biosolutions' return on equity of 10.76% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Summary

Emergent Biosolutions beats OPKO Health on 10 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$394.22M	$3.64B	$6.80B	$23.38B
Dividend Yield	N/A	2.16%	2.67%	4.15%
P/E Ratio	-27.29	20.61	27.08	30.83
Price / Sales	0.53	304.69	516.47	20.33
Price / Cash	2.08	60.31	26.68	18.81
Price / Book	0.77	8.04	10.63	4.75
Net Income	$52.60M	$23.81M	$3.60B	$1.07B
7 Day Performance	1.53%	-1.31%	-1.08%	0.01%
1 Month Performance	-4.43%	2.48%	1.28%	1.05%
1 Year Performance	10.21%	44.40%	24.71%	17.32%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	1.975 of 5 stars	$7.64 -0.7%	$12.00 +57.1%	+10.7%	$394.22M	$742.90M	N/A	2,420
JNJ Johnson & Johnson	4.6243 of 5 stars	$257.82 +0.3%	$261.26 +1.3%	+52.1%	$618.61B	$94.19B	29.81	138,200	Earnings Report Dividend Announcement Analyst Upgrade
INVA Innoviva	2.9333 of 5 stars	$22.21 -0.1%	$36.20 +63.0%	+8.7%	$1.64B	$411.33M	3.70	100
NVAX Novavax	2.127 of 5 stars	$8.91 -4.5%	$13.00 +45.9%	+12.6%	$1.53B	$1.12B	N/A	1,990
MNKD MannKind	3.618 of 5 stars	$4.04 -1.2%	$8.97 +122.0%	+5.9%	$1.26B	$348.97M	N/A	400	News Coverage Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, INVA, NVAX, MNKD, and OPK

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Innoviva?

Summary

How does Emergent Biosolutions compare to Novavax?

Summary

How does Emergent Biosolutions compare to MannKind?

Summary

How does Emergent Biosolutions compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, INVA, NVAX, MNKD, and OPK

How does Emergent Biosolutions compare to Johnson & Johnson?

Which has more risk & volatility, JNJ or EBS?

Does the media prefer JNJ or EBS?

Do institutionals & insiders believe in JNJ or EBS?

Is JNJ or EBS more profitable?

Do analysts recommend JNJ or EBS?

Which has stronger earnings and valuation, JNJ or EBS?

Summary

How does Emergent Biosolutions compare to Innoviva?

Which has more volatility and risk, INVA or EBS?

Is INVA or EBS more profitable?

Do institutionals and insiders hold more shares of INVA or EBS?

Which has stronger valuation & earnings, INVA or EBS?

Do analysts rate INVA or EBS?

Does the media refer more to INVA or EBS?

Summary

How does Emergent Biosolutions compare to Novavax?

Do analysts recommend EBS or NVAX?

Does the media favor EBS or NVAX?

Is EBS or NVAX more profitable?

Which has more volatility and risk, EBS or NVAX?

Which has higher valuation and earnings, EBS or NVAX?

Do institutionals & insiders have more ownership in EBS or NVAX?

Summary

How does Emergent Biosolutions compare to MannKind?

Which has preferable earnings and valuation, MNKD or EBS?

Does the media prefer MNKD or EBS?

Which has more volatility and risk, MNKD or EBS?

Is MNKD or EBS more profitable?

Do institutionals and insiders have more ownership in MNKD or EBS?

Do analysts rate MNKD or EBS?

Summary

How does Emergent Biosolutions compare to OPKO Health?

Which has stronger valuation & earnings, OPK or EBS?

Does the media prefer OPK or EBS?

Do institutionals & insiders believe in OPK or EBS?

Which has more volatility & risk, OPK or EBS?

Do analysts rate OPK or EBS?

Is OPK or EBS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools